Sjögren's disease & overlap diseases
Clinical and prognostic features associated with anti-Ro52 autoantibodies in connective tissue diseases patients with interstitial lung disease
Authors' conclusion
Anti-Ro52 antibodies may predict more severe lung damage in CTD-ILD; however, anti-Ro52 antibodies were not correlated with progression and death in patients with ILD.
Study context
- Population
- Patients with connective tissue diseases with ILD (connective tissue diseases with interstitial lung disease (CTD-ILD))170 with follow-up
- Participants
- 238 patients
- Exposure
- Anti-Ro52 positive vs anti-Ro52 negative CTD-ILD
- Anti-Ro52 positiven = 145
- Outcome
- Clinical features at baseline
- Follow-up
- Baseline
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Anti-Ro52 positive more likely to have respiratory symptoms, more organising pneumonia patterns and worse forced vital capacity (FVC)
Observational data: associations, not effects.
Further findings
Mortality during follow-up
log-rank p=0.287
- Mortality during follow-up: 35 deaths among 170 followed
ILD progression (pulmonary function (PF) or imaging)
- Progression in 48 of 170 patients with CTD-ILD
- 28.24%
- No correlation of progression with anti-Ro52 antibodies (logistic analysis)
Factors associated with ILD progression (multivariate logistic analysis)
- Older age, worse baseline FVC and DLCO, higher CRP, serum ferritin, IgG and lower absolute lymphocyte count
Original publication
Clinical and prognostic features associated with anti-Ro52 autoantibodies in connective tissue diseases patients with interstitial lung disease. Clin Exp Rheumatol. Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →